The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
Open accessAbstract
Background The selective TRK inhibitor larotrectinib was approved for paediatric and adult patients with advanced TRK fusion-positive solid tumours based on a primary analysis set of 55 patients. The aim of our analysis was to explore the efficacy and long-term safety of larotrectinib in a larger population of patients with TRK fusion-positive solid tumours.Methods Patients were enrolled and treated in a phase 1 adult, a phase 1/2 paediatric, or a phase 2 adolescent and adult trial. Some eligibility criteria differed between these studies. For this pooled analysis, eligible patients were aged 1 month or older, with a locally advanced or metastatic non-CNS primary, TRK fusion-positive solid tumour, who had received standard therapy previously if available. This analysis set includes the 55 patients on which approval of larotrectinib was based. Larotrectinib was administered orally (capsule or liquid formulation), on a continuous 28-day schedule, to adults mostly at a dose of 100 mg twice daily, and to paediatric patients mostly at a dose of 100 mg/m 2 (maximum of 100 mg) twice daily. The primary endpoint was objective response as assessed by local investigators in an intention-to-treat analysis. Contributing trials are registered with ClinicalTrials.gov, NCT02122913 (active not recruiting), NCT02637687 (recruiting), and NCT02576431 (recruiting).Findings Between May 1, 2014, and Feb 19, 2019, 159 patients with TRK fusion-positive cancer were enrolled and treated with larotrectinib. Ages ranged from less than 1 month to 84 years. The proportion of patients with an objective response according to investigator assessment was 121 (79%, 95% CI 72-85) of 153 evaluable patients, with 24 (16%) having complete responses. In a safety population of 260 patients treated regardless of TRK fusion status, the most common grade 3 or 4 larotrectinib-related adverse events were increased alanine aminotransferase (eight [3%] of 260 patients), anaemia (six, 2%), and decreased neutrophil count (five [2%]). The most common larotrectinib-related serious adverse events were increased alanine aminotransferase (two [<1%] of 260 patients), increased aspartate aminotransferase (two [<1%]), and nausea (two [<1%]). No treatment-related deaths occurred.Interpretation These data confirm that TRK fusions define a unique molecular subgroup of advanced solid tumours for which larotrectinib is highly active. Safety data indicate that long-term administration of larotrectinib is feasible.Funding Bayer and Loxo Oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this trial, 8 of 159 patients had colon cancer”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“with a median duration of 3.7 months.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“Nevertheless, entrectinib and lartotrectinib have demonstrated activity in patients with solid tumors with NTRK fusion”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“4 patients with colon cancer had a response to therapy”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“and the FDA has approved their use for these patients.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“Two therapies, larotrectinib and entrectinib, are FDA-approved for use in CRC with NTRK mutation.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“Based on the efficacy across tumor types, larotrectinib was FDA-approved for tumors with NTRK fusions, including CRC.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Self-citationAlectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
NTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. E. D. C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,521
Self-citationSkálová, A., Vaněček, T., Šíma, R., Laco, J., Weinreb, I., Perez‐Ordoñez, B., Stárek, I., Geierová, M., Simpson, R. H., Passador‐Santos, F., et al. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181d9efcc · Cited by 1,017
Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma
Tognon, C. E., Knezevich, S. R., Huntsman, D. D., Roskelley, C. D., Melnyk, N., Mathers, J. A., Becker, L. E., Carneiro, F., Macpherson, N. A., Horsman, D. E., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00180-0 · Cited by 908
Drilon, A. E. D. C., Siena, S., Ou, S. I., Patel, M. R., Ahn, M., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1237 · Cited by 833
Self-citation
Research works printed but not linked: 1
- Geoerger, 2019, Larotrectinib efficacyand safety in pediatric patients with TRK fusion cancer, Pediatr Blood Cancer, 66, S4
Cited by
Sorted by citations
Items 401–500 of 1,000
Pancreatic adenocarcinoma: Beyond first line, where are we?
Cherri, S., Noventa, S., & Zaniboni, A. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i17.1847 · Cited by 13
Mechanisms of targeted therapy resistance in a pediatric glioma driven by ETV6-NTRK3 fusionPreprint
Keddy, C., Neff, T. L., Huan, J., Nickerson, J. P., Beach, C. Z., Akkari, Y. M. N., Ji, J., Moore, S. R., Nazemi, K. J., Corless, C. L., et al. (2021) · Molecular Case Studies · doi:10.1101/mcs.a006109 · Cited by 13
Porta, C., Pradelli, L., Sicari, E., Castellani, S., Sivakumar, S., Sokol, E. S., Montesion, M., Wieland, T., Rambichler, J., Minari, R., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107359 · Cited by 12
Multidisciplinary Standards and Evolving Therapies for Patients With Pancreatic Cancer
Safyan, R. A., Kim, E., Dekker, E. N., Homs, M. Y. V., Aguirre, A. J., Koerkamp, B. G., & Chiorean, E. G. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_438598 · Cited by 12
Waliany, S., Hung, Y. P., Rous, F. A., Luo, F., Capelletti, M., Ressler, S. J., Do, A., Peterson, J., Meservey, C., Digumarthy, S. R., et al. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.03.009 · Cited by 12
Biomarkers and Management of Cholangiocarcinoma: Unveiling New Horizons for Precision Therapy
Nishida, N. (2025) · Cancers · doi:10.3390/cancers17071243 · Cited by 12
Intersection between lung cancer and neuroscience: Opportunities and challenges
Xiao, X., Huang, L., Li, M., & Zhang, Q. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217701 · Cited by 12
Juthani, R., & Manne, A. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1555963 · Cited by 12
van der Graaf, W. T. A., Heiss, N. S., Hynes, C. L., Keller, S. M., Weinman, A., Blay, J., Franco, P., Giles, R. H., Lacombe, D. A., Schlatter, P., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103013 · Cited by 12
Kumar, V., Meenu, Shaquiquzzaman, M., Alam, M. A., Akhter, M., Parveen, D., Kaleem, M., Charan, S., Saifullah, M. K., & Tasneem, S. (2026) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2026.110527 · Cited by 12
Genomic Therapy Matching in Rare and Refractory Cancers
Lin, F. P., Thavaneswaran, S., Grady, J. P., Napier, C. E., Kansara, M., Sebastian, L. T., Kee, D., Desai, J., Zaheed, M., Chinchen, S., et al. (2026) · JAMA Oncology · doi:10.1001/jamaoncol.2026.0127 · Cited by 12
Impact of Precision Medicine on Clinical Outcomes: A Single-Institution Retrospective Study
Quinn, R., Patel, R., Sison, C. P., Singh, A., & Zhu, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.659113 · Cited by 12
Rudzinski, E. R., Hechtman, J. F., Roy‐Chowdhuri, S., Rudolph, M., Lockwood, C. M., Silvertown, J. D., Wierzbińska, J. A., Shen, K., Norenberg, R., Nogai, H., et al. (2021) · Cancer Genetics · doi:10.1016/j.cancergen.2021.11.006 · Cited by 12
Self-citationLi, H., Li, W., Zhang, L., He, J., Tang, L., Li, Z., Chen, F., Fan, Q., & Wei, J. (2022) · Journal of Oncology · doi:10.1155/2022/4407541 · Cited by 12
Berker, Y., ElHarouni, D., Peterziel, H., Fiesel, P., Witt, O., Oehme, I., Schlesner, M., & Oppermann, S. (2022) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2022.3205554 · Cited by 12
Self-citationMedford, A. J., Oshry, L. J., Boyraz, B., Kiedrowski, L. A., Menshikova, S., Butusova, A., Dai, C. S., Gogakos, T., Keenan, J. C., Abelman, R. O., et al. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231152844 · Cited by 12
Kokkali, S., Georgaki, E., Mandrakis, G., Valverde, C. M., & Theocharis, S. E. (2023) · Cells · doi:10.3390/cells12222632 · Cited by 12
Katabi, N. (2024) · Head and Neck Pathology · doi:10.1007/s12105-024-01622-9 · Cited by 12
NTRK fusions are extremely rare in bone tumours
Lam, S. W., Bruijn, I. H. B., van Wezel, T., Cleven, A. H. G., Hogendoorn, P. C. W., Cleton-Jansen, A., & Bovée, J. V. M. G. (2021) · Histopathology · doi:10.1111/his.14432 · Cited by 12
Update on Superficial Spindle Cell Mesenchymal Tumors in Children
Drabent, P., & Fraitag, S. (2021) · Dermatopathology · doi:10.3390/dermatopathology8030035 · Cited by 12
Fusion Oncoproteins in Childhood Cancers: Potential Role in Targeted Therapy
Angione, S. D. A., Akalu, A. Y., Gartrell, J., Fletcher, E. P., Burckart, G. J., Reaman, G. H., Leong, R., & Stewart, C. F. (2021) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-26.6.541 · Cited by 12
The potential targeted drugs for fusion genes including NRG1 in pancreatic cancer
Umemoto, K., & Sunakawa, Y. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103465 · Cited by 12
De, B. S., Abu-Gheida, I. H., Patel, A., Ng, S. S. W., Zaid, M., Thunshelle, C. P., Elganainy, D., Corrigan, K. L., Rooney, M. K., Javle, M. M., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121270 · Cited by 12
Genomic comparison of malignant melanoma and atypical Spitz tumor in the pediatric population
Church, A. J., Moustafa, D., Pinches, R. S., Hawryluk, E. B., & Schmidt, B. A. R. (2022) · Pediatric Dermatology · doi:10.1111/pde.14935 · Cited by 12
Application of histology-agnostic treatments in metastatic colorectal cancer
Bianchi, A. S., Agostara, A. G., Patelli, G., Mauri, G., Pizzutilo, E. G., & Siena, S. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.05.013 · Cited by 12
Trigo, J. M., García‐Cosío, M., García‐Castaño, A., Gomà, M., Mesía, R., Ruiz‐Bravo, E., Soria-Rivas, A., Castillo, P., Braña, I., & Alberola‐Ferranti, M. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02856-1 · Cited by 12
Lim, K. H. T., Kong, H. L., Chang, K. T. E., Tan, D. S. W., Tan, I. B. H., Farid, M., Soh, S. Y., Pang, B., Soo, R. A., Choo, S. P., et al. (2021) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13727 · Cited by 12
Wu, S., Liu, Y., Li, K., Liang, Z., & Zeng, X. (2023) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2023.04.007 · Cited by 11
Zhou, S., Zhang, F., Xu, M., Zhang, L., Liu, Z., Yang, Q., Wang, C., Wang, B., Ma, T., & Feng, J. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13509 · Cited by 11
Amemiya, K., Hirotsu, Y., Nagakubo, Y., Mochizuki, H., Oyama, T., & Omata, M. (2023) · Pathology International · doi:10.1111/pin.13385 · Cited by 11
Current Status of Targeted Therapy for Biliary Tract Cancer in the Era of Precision Medicine
Mie, T., Sasaki, T., Okamoto, T., Furukawa, T., Takeda, T., Kasuga, A., Ozaka, M., & Sasahira, N. (2024) · Cancers · doi:10.3390/cancers16050879 · Cited by 11
Wang, X., Bai, L., Kong, L., & Guo, Z. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1411731 · Cited by 11
Gene Mutations in Gastrointestinal Stromal Tumors: Advances in Treatment and Mechanism Research
Cao, L., Tian, W., Zhao, Y., Song, P., Zhao, J. Y., Wang, C., Liu, Y., Fang, H., & Liu, X. (2024) · Global Medical Genetics · doi:10.1055/s-0044-1789204 · Cited by 11
Is Autophagy Targeting a Valid Adjuvant Strategy in Conjunction with Tyrosine Kinase Inhibitors?
Elshazly, A. M., Xu, J., Melhem, N. Y., Abdulnaby, A., Elzahed, A. A., Saleh, T., & Gewirtz, D. A. (2024) · Cancers · doi:10.3390/cancers16172989 · Cited by 11
Zhao, K., Sun, T., Sun, Q., Chen, Z., Wang, T., Yang, J., Li, L., Zhu, Y., Liu, X., Yang, D., et al. (2024) · Advanced Science · doi:10.1002/advs.202414437 · Cited by 11
Yoon, H., & Yoo, C. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70208 · Cited by 11
Raghavendra, A. S., Damodaran, S., Barcenas, C. H., Fuqua, S. A. W., Layman, R. M., & Tripathy, D. (2026) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70055 · Cited by 11
Yoo, J., Kim, H. J., Kim, S., & Park, H. H. (2022) · European Thyroid Journal · doi:10.1530/etj-22-0087 · Cited by 11
Suh, K., Carlson, J. J., Xia, F., Williamson, T. E., & Sullivan, S. D. (2022) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2021-0247 · Cited by 11
Why will there never be a randomized trial for NTRK-rearranged tumors?
Penel, N., Lebellec, L., & Blay, J. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.04.001 · Cited by 11
Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation
Su, Y., Chiang, N., Chiu, T., Huang, C., Hsu, S., Lin, H., Yang, S., Yang, Y., Chou, W., Chen, Y., et al. (2023) · Biomedical Journal · doi:10.1016/j.bj.2023.100696 · Cited by 11
Boldig, C. M., Boldig, K., Mokhtari, S., & Etame, A. B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136961 · Cited by 11
Treatment of Rare Mutations in Patients with Lung Cancer
Taha, T., Khoury, R., Brenner, R. M., Nasrallah, H., Shofaniyeh, I., Yousef, S., & Agbarya, A. (2021) · Biomedicines · doi:10.3390/biomedicines9050534 · Cited by 11
Pestana, R. C., Roszik, J., Groisberg, R., Sen, S., Tine, B. A. V., Conley, A. P., & Subbiah, V. (2021) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2021.100794 · Cited by 11
Kasi, P. M., Afghan, M. K., Bellizzi, A. M., & Chan, C. H. F. (2022) · Cureus · doi:10.7759/cureus.26648 · Cited by 11
Schirizzi, A., Leonardis, G. D., Lorusso, V., Donghia, R., Rizzo, A., Vallarelli, S., Ostuni, C., Troiani, L., Lolli, I. R., Giannelli, G., et al. (2023) · Cancers · doi:10.3390/cancers15082376 · Cited by 11
Bill, R., Deschler, D. G., Pittet, M. J., Pai, S. I., Sadow, P. M., & Park, J. C. (2021) · Cancer Reports · doi:10.1002/cnr2.1491 · Cited by 11
Isolated Leptomeningeal Progression in a Patient with NTRK Fusion+ Uterine Sarcoma: A Case Report
Lanman, T. A., Gephart, M. H., Bui, N. Q., Toland, A. M. S., & Nagpal, S. (2021) · Case Reports in Oncology · doi:10.1159/000521158 · Cited by 11
Önnestam, K., Nilsson, B., Rother, M., Rein-Hedin, E., Bylund, J., Anderer, P., Kemethofer, M., Halldin, M. M., Sandin, J., & Segerdahl, M. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.89 · Cited by 10
Dhaenens, B. A. E., Mahler, F., Batchelor, H. K., Dicks, P., Gaillard, S., Nafría, B., Kopp‐Schneider, A., Ribeiro, M. A., Schwab, M. G., Sparber‐Sauer, M., et al. (2023) · Clinical and Translational Science · doi:10.1111/cts.13547 · Cited by 10
Tissue-Agnostic Cancer Therapy Approvals
Gouda, M. A., & Subbiah, V. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2026.05.016 · Cited by 10
Gray, C. M., Ralphs, E., Fox, M. P., Lash, T. L., Liu, G., Kou, T. D., Rivera, D. R. R., Bosco, J. L. F., Braun, K. V. N., Grimson, F., et al. (2024) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5796 · Cited by 10
Švec, J., Onhajzer, J., & Kořínek, V. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104544 · Cited by 10
Advances in the Treatment of Rare Mutations in Non-Small Cell Lung Cancer
Sun, Y., Ma, L., Zhang, X., & Wang, Z. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s487870 · Cited by 10
Kubota, Y., Kawano, M., Iwasaki, T., Itonaga, I., Kaku, N., Ozaki, T., & Tanaka, K. (2025) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaf015 · Cited by 10
Prognostic Biomarkers in Isocitrate Dehydrogenase Wild-Type Glioblastoma: A Focus on B7-H3
Yüceer, R. O., Kaya, Ş., Balcı, S. N., Eğilmez, H. R., Yılmaz, M., & Erdiş, E. (2025) · Brain Sciences · doi:10.3390/brainsci15020212 · Cited by 10
Lu, X., Xu, S., Deng, Z., Wang, M., & Chen, F. (2025) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbaf021 · Cited by 10
Targeted therapies and checkpoint inhibitors in sarcoma
Vasella, M., Gousopoulos, E., Guidi, M., Storti, G., Song, S. Y., Grieb, G., Pauli, C., Lindenblatt, N., Giovanoli, P., & Kim, B. S. (2021) · QJM · doi:10.1093/qjmed/hcab014 · Cited by 10
Emerging drugs for the treatment of radioactive iodine refractory papillary thyroid cancer
Leboulleux, S., Lamartina, L., Hadoux, J., Baudin, É., & Schlumberger, M. J. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2071696 · Cited by 10
Teixeira, M. R., Oliveira, J., Borralho, P., Fernandes, M. G. O., Almodôvar, T., Fernandes, I., Macedo, D., Ferreira, A. E. F., Barroso, A., Teixeira, E., et al. (2022) · Acta Médica Portuguesa · doi:10.20344/amp.17680 · Cited by 10
Wang, J., Wang, L., Zhu, J., Ren, J., Wang, D., & Luo, M. (2022) · Respirology Case Reports · doi:10.1002/rcr2.1054 · Cited by 10
Dazio, G., Epistolio, S., Frattini, M., & Saletti, P. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11247523 · Cited by 10
Bokemeyer, C., Paracha, N., Lassen, U., Italiano, A., Sullivan, S. D., Marian, M., Brega, N. M., & García‐Foncillas, J. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00436 · Cited by 10
Zhou, K. I., Vashistha, V., Guo, A., Ahmed, S., & Kelley, M. J. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00692 · Cited by 10
Advances in the treatment of solid tumors in children and adolescents
Tian, J., Wang, J., & Li, S. (2023) · Cancer Innovation · doi:10.1002/cai2.66 · Cited by 10
Safety of current treatment options for NTRK fusion-positive cancers
Yang, A. T., & Laetsch, T. W. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2274426 · Cited by 10
Self-citationNISCAHN: a phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08)
Fayette, J., Even, C., Digue, L., Geoffrois, L., Rolland, F., Cupissol, D., Guigay, J., Tourneau, C. L., Dillies, A. F., Zanetta, S., et al. (2023) · BMJ Oncology · doi:10.1136/bmjonc-2023-000065 · Cited by 10
Kokkali, S., Boukovinas, I., de Bree, E., Koumarianou, A. A., Georgoulias, V., Kyriazoglou, A. I., Tsoukalas, N., Memos, N. A., Papanastassiou, I. D., Stergioula, A., et al. (2024) · Cancers · doi:10.3390/cancers16132314 · Cited by 10
Dell’Anno, F., Giugliano, R., Listorti, V., & Razzuoli, E. (2024) · Veterinary Sciences · doi:10.3390/vetsci11080362 · Cited by 10
Genomic Analysis of Salivary Gland Cancer and Treatment of Salivary Gland Cancers
Palsgrove, D. N., Allahabadi, S., & Khan, S. A. (2021) · Surgical pathology clinics · doi:10.1016/j.path.2020.10.001 · Cited by 10
Emerging systemic antitarget treatment for differentiated thyroid carcinoma
Basté, N., Mora, M., & Grau, J. J. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000727 · Cited by 10
Tartarone, A., Lapadula, V., Micco, C. D., Rossi, G., Ottanelli, C., Marini, A., Giorgione, R., Ferrari, K., Catalano, M., Voltolini, L., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.632256 · Cited by 10
Gene fusions in tumourigenesis with particular reference to ovarian cancer
Zhou, Y., & El-Bahrawy, M. A. (2021) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2021-108010 · Cited by 10
Su, Y.-J., Lee, Y.-H., Jin, Y.-T., & Hsieh, M.-S. (2021) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000001003 · Cited by 10
Peh, K. H., Przybylski, D. J., Fallon, M. J., Bergsbaken, J., Hutson, P. R., Yu, M., Deming, D. A., & Burkard, M. E. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221091282 · Cited by 10
Zhou, J., Wang, W., Zhang, H., Gao, Q., Wang, W., Zhu, J.-H., Han, Y., Chen, J., Ma, T., Zhang, X., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1138100 · Cited by 10
Management of radioiodine refractory differentiated thyroid cancer: the Latin American perspective
Pitoia, F., Scheffel, R. S., Califano, I., Gauna, A., Tala, H., Vaisman, F., Román-Gonzaléz, A., Hoff, A. O., & Maia, A. L. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09818-0 · Cited by 10
Targeted therapy of non-small cell lung cancer
Svatoň, M. (2021) · Klinicka onkologie · doi:10.48095/ccko2021s48 · Cited by 10
Larotrectinib in a Patient With Advanced Pleomorphic Liposarcoma of the Uterus
Valenciaga, A., Iwenofu, O. H., & Tinoco, G. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.7039 · Cited by 10
Parrish, R. H., Ashworth, L. D., Löbenberg, R., Benavides, S., Cies, J. J., & MacArthur, R. B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051032 · Cited by 10
Bridgewater, J. A., Jiao, X., Parimi, M., Flach, C., Stratford, J. K., Kamburov, A., Schmitz, A. A. P., Zong, J., Reeves, J. A., Keating, K. N., et al. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100623 · Cited by 10
Svrcek, M., Cayre, A., Samaille, T., Colle, R., Mas, L., Bourgoin, P., Guillerm, E., Cohen, R., Penault-Llorca, F. M., André, T., et al. (2024) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2024.100084 · Cited by 9
ERK signaling promotes resistance to TRK kinase inhibition in NTRK fusion-driven glioma mouse models
Schmid, S., Russell, Z. R., Yamashita, A. S., West, M. E., Parrish, A. G., Walker, J. R., Rudoy, D., Yan, J. Z., Quist, D. C., Gessesse, B. N., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114829 · Cited by 9
Treatment Innovations in Pancreatic Cancer: Putting Patient Priorities First
Reiss, K. A., Soares, K. C., Torphy, R. J., & Gyawali, B. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473204 · Cited by 9
Actionable mutations in pancreatic cancer: where targeted therapies are making a difference
Fivaz, M., Bornand, A., Corrò, C., Koessler, T., & Genoud, V. (2025) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2025-001925 · Cited by 9
Geoerger, B., Marshall, L. V., Nysom, K., Makin, G., Bouffet, É., Defachelles, A. S., Amoroso, L., Aerts, I., Leblond, P., Barahona, P., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.04.007 · Cited by 9
Self-citationNaito, Y., Mishima, S., Akagi, K., Hayashi, N., Hirasawa, A., Hishiki, T., Igarashi, A., Ikeda, M., Kadowaki, S., Kajiyama, H., et al. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02345-7 · Cited by 9
Palmerini, E., Frega, G., Gambarotti, M., Frisoni, T., Cesari, M., Bazzocchi, A., Miceli, M., Donati, D. M., Fanti, S., Nanni, C., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1252359 · Cited by 9
Nilsson, B., Bylund, J., Halldin, M. M., Rother, M., Rein‐Hedin, E., Önnestam, K., & Segerdahl, M. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03645-1 · Cited by 9
Iwaki, S., Kawakita, D., Nagao, T., Tada, Y., Honma, Y., Ando, M., Matoba, T., Minohara, K., Nakano, S., Murase, T., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.34972 · Cited by 9
Scholfield, D. W., Fitzgerald, C. W. R., Boe, L. A., Eagan, A. J., Levyn, H., Xu, B., Tuttle, R. M., Fagin, J. A., Shaha, A. R., Shah, J. P., et al. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-15500-9 · Cited by 9
Histology Agnostic Drug Development: An Updated Review
Nguyen, K., Fama, K. B., Mercado, G., Myat, Y. M., & Thein, K. Z. (2024) · Cancers · doi:10.3390/cancers16213642 · Cited by 9
Targeting stromal cells in tumor microenvironment as a novel treatment strategy for glioma
Geng, Z., Zhang, Z., Wang, M., Yu, Z., Wang, S., Lu, J., Wang, S., Guan, S., Li, J., Liu, T., et al. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03692-3 · Cited by 9
The Role of Liquid Biopsy in the Management of Patients with Genitourinary Malignancies
Maughan, B. L., Dyrskjøt, L., Grivas, P. D., Alcaraz, A., Antonarakis, E. S., Bilen, M. A., Bivalacqua, T. J., Cooperberg, M. R., Liang Cheng, C., & Gupta, S. (2025) · European Urology · doi:10.1016/j.eururo.2025.07.016 · Cited by 9
Evolution of anaplastic thyroid cancer management: perspectives in the era of precision oncology
Salgado, S. A. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211054692 · Cited by 9
Artificial intelligence, molecular subtyping, biomarkers, and precision oncology
Shen, J. P. (2021) · Emerging Topics in Life Sciences · doi:10.1042/etls20210212 · Cited by 9
Mauri, D., Kamposioras, K. V., Matthaios, D., Tolia, M., Nixon, I., Dambrosio, M., Zarkavelis, G., Papadimitriou, K., Petričević, B., Kountourakis, P., et al. (2022) · Oncology Research and Treatment · doi:10.1159/000521845 · Cited by 9
NTRK-fusions in pediatric thyroid tumors: Current state and future perspectives
Casado‐Medrano, V., O’Neill, A., Halada, S., Laetsch, T. W., Bauer, A. J., & Franco, A. T. (2022) · Cancer Genetics · doi:10.1016/j.cancergen.2022.02.009 · Cited by 9
Self-citationPestana, R. C., & Serrano, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1079909 · Cited by 9
Lorusso, L., Minaldi, E., Esposito, G., Piaggi, P., Bottici, V., Brogioni, S., Giani, C., Valerio, L., Molinaro, E., Elisei, R., et al. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02076-6 · Cited by 9
Metadata
- Authors
- Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R., Berlin, J. D., Federman, N., Mascarenhas, L., Geoerger, B., Dowlati, A., Pappo, A. S., Bielack, S., Doz, F., McDermott, R., Patel, J. D., Schilder, R. J., Tahara, M., Pfister, S. M., Witt, O., Ladanyi, M., Rudzinski, E. R., Nanda, S., Childs, B. H., Laetsch, T. W., Hyman, D. M., & Drilon, A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- Stanford Medicine (US)
- Massachusetts General Hospital (US)
- Seattle Children's Hospital (US)
- University of Copenhagen (DK)
- Vanderbilt University Medical Center (US)
- University of California, Los Angeles (US)
- University of Southern California (US)
- Université Paris-Saclay (FR)
- University Hospitals Cleveland Medical Center (US)
- St. Jude Children's Research Hospital (US)
- Olgahospital (DE)
- Université Paris Descartes (FR)
- Cancer Trials Ireland (IE)
- University of Chicago (US)
- Thomas Jefferson University (US)
- National Cancer Center Hospital East (JP)
- German Cancer Research Center (DE)
- Memorial Sloan Kettering Cancer Center (US)
- Bayer (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Drilon, Alexander
- ORCID
- Hong, David S
- DuBois, Steven G
- Kummar, Shivaani
- Farago, Anna F
- Albert, Catherine M
- Rohrberg, Kristoffer S
- Nagasubramanian, Ramamoorthy
- Berlin, Jordan D
- Federman, Noah
- Mascarenhas, Leo
- Geoerger, Birgit
- Dowlati, Afshin
- Pappo, Alberto S
- Bielack, Stefan
- Doz, François
- McDermott, Ray
- Patel, Jyoti D
- Tahara, Makoto
- Pfister, Stefan M
- Witt, Olaf
- Ladanyi, Marc
- Rudzinski, Erin R
- Nanda, Shivani
- Childs, Barrett H
- Laetsch, Theodore W
- Hyman, David M
- Drilon, Alexander
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 21
- Issue
- 4
- Pages
- 531-540
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC7497841
- OpenAlex
- W3008107700
- Cited by
- 1,028
- References
- 25
- Citations by year
- 2026: 106 · 2025: 148 · 2024: 162 · 2023: 178 · 2022: 202 · 2021: 171 · 2020: 60
- FWCI
- 86.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Loxo Oncology
- Bayer Corporation
- Bayer Fund
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- larotrectinib, TRK inhibitors, objective response rate, long-term safety, adverse events, childhood cancer, adult cancer, metastatic cancer, pooled analysis of clinical trials, alanine aminotransferase elevation, neutropenia, anemia, complete response, dose-limiting toxicity
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Neoplasms, Proteins, Pyrazoles, Pyrimidines, Vesicular Transport Proteins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
